XML 36 R13.htm IDEA: XBRL DOCUMENT
v3.25.4

FAIR VALUE MEASUREMENT | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2025 | Dec. 31, 2024
Investments, All Other Investments [Abstract] |  |
FAIR VALUE MEASUREMENT | NOTE 5 – FAIR VALUE MEASUREMENT On September 30, 2025 and December 31, 2024, the Company estimated the aggregate fair value of warrants that are accounted for as warrant liabilities to be $1,968,315 and $2,520,851, respectively, using the Black-Scholes option price model (Level 3 inputs). The Company recognized a gain on the change in fair value of these warrant liabilities of $612,064 and $552,536 for the three and nine months ended September 30, 2025, respectively. The Company recognized a gain (loss) on the change in fair value of these warrant liabilities of $1,036,464 and ($837,466) for the three and nine months ended September 30, 2024, respectively. The following table shows the detail of the valuation assumptions used as of September 30, 2025: SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS
|  | September 30, 2025 |
Risk free interest rate |  |  | 3.63%-3.68% |
Expected term (years) |  |  | 1.11 - 3.36 |
Expected volatility |  |  | 71% - 95% |
Expected dividends |  |  | 0.00% |
SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS The following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring basis during the three months ended September 30, 2025 and three months ended September 30, 2024:
|  | 2025 |  |  | 2024 |
|  | For the Three Months Ended September 30, |
|  | 2025 |  |  | 2024 |
Balance, July 1, |  | $ | 2,580,379 |  |  | $ | 4,491,969 |
Issuance of warrants |  |  |  |  |  |  |  |
Exercise of warrants |  |  |  |  |  |  |  |
Change in fair value of warrant liability |  |  | (612,064 | ) |  |  | (1,036,464 | )
Balance, September 30, |  | $ | 1,968,315 |  |  | $ | 3,455,505 |
The following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring basis during the nine months ended September 30, 2025 and nine months ended September 30, 2024:
|  | 2025 |  |  | 2024 |
|  | For the Nine Months ended September 30, |
|  | 2025 |  |  | 2024 |
Balance, January 1, |  | $ | 2,520,851 |  |  | $ | 2,618,039 |
Change in fair value of warrant liability |  |  | (552,536 | ) |  |  | 837,466 |
Balance, September 30, |  | $ | 1,968,315 |  |  | $ | 3,455,505 |
Assets and liabilities measured at fair value on a recurring basis are as follows: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS
|  | Fair value measurements at reporting date using: |
|  | Quoted prices in active markets for identical liabilities (Level 1) |  |  | Significant other observable inputs (Level 2) |  |  | Significant unobservable inputs (Level 3) |  |  | Total Fair Value |
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Marketable securities as of September 30, 2025 |  | $ | 3,887,383 |  |  | $ | - |  |  | $ | - |  |  | $ | 3,887,383 |
Marketable securities as of December 31, 2024 |  | $ | 10,184,701 |  |  | $ | - |  |  | $ | - |  |  | $ | 10,184,701 |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant liabilities as of September 30, 2025 |  | $ | - |  |  | $ | - |  |  | $ | 1,968,315 |  |  | $ | 1,968,315 |
Warrant liabilities as of December 31, 2024 |  | $ | - |  |  | $ | - |  |  | $ | 2,520,851 |  |  | $ | 2,520,851 |
| NOTE 9 – FAIR VALUE MEASUREMENT The Company accounts for the Warrants as liabilities in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity. For certain Warrants, the Company does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the Warrants and not result in a change of control of the Company. As a result, such Warrants do not meet the criteria for equity treatment and the Warrants must be recorded as a derivative liability. Additionally, certain other Warrants contain adjustments to the settlement amount based on a variable that is not an input to the fair value of a “fixed-for-fixed” option as defined under ASC 815-40 and, accordingly, such Warrants are not considered indexed to the Company’s own stock and are not eligible for an exception from derivative accounting. On February 8, 2024, in connection with the Warrant Exercise and Issuance, the Company estimated the aggregate fair value of the Existing Warrants (see Note 6- Stockholders’ Equity for details) to be $1,115,334 using the Black-Scholes option pricing model (Level 3 inputs). The following table shows the detail of the valuation assumptions used: SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS
|  | February 8, 2024 |
Risk free interest rate |  |  | 4.20 - 4.28 | %
Expected term (years) |  |  | 2.75 - 2.76 |
Expected volatility |  |  | 102 | %
Expected dividends |  |  | 0.00 | %
On February 8, 2024, the Company estimated the aggregate issuance date fair value of the warrant liability related to the New Warrants (see Note 4 - Stockholders’ Equity for details) as $2,189,420 using the Black-Scholes option pricing model (Level 3 inputs). The following table shows the detail of the valuation assumptions used:
|  | February 8, 2024 |
Risk free interest rate |  |  | 4.12 | %
Expected term (years) |  |  | 5.00 |
Expected volatility |  |  | 101 | %
Expected dividends |  |  | 0.00 | %
On December 31, 2024 and 2023, the Company estimated the aggregate fair value of the warrants classified as derivative liabilities to purchase an aggregate of 3,900,014 and 4,737,908 shares of common stock, respectively, to be $2,520,851 and $1,543,953, respectively, using the Black-Scholes option pricing model (Level 3 inputs) using the following assumptions:
|  | December 31, |
|  | 2024 |  |  | 2023 |
Risk free interest rate |  |  | 4.12% - 4.34 | % |  |  | 4.04 | %
Expected term (years) |  |  | 1.86 - 4.11 |  |  |  | 2.86 |
Expected volatility |  |  | 97% - 110 | % |  |  | 87.00 | %
Expected dividends |  |  | 0.00 | % |  |  | 0.00 | %
The following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring basis during the years ended December 31, 2024 and 2023: SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS
Balance, January 1, 2023 |  | $ | 5,541,733 |
Change in fair value of derivative liability |  |  | (3,997,780 | )
Balance, January 1, 2024 |  |  | 1,543,953 |
Issuance of warrants |  |  | 2,189,420 |
Exercise of warrants |  |  | (1,115,334 | )
Change in fair value of warrant liability |  |  | (97,188 | )
Balance, December 31, 2024 |  | $ | 2,520,851 |
Assets and liabilities measured at fair value on a recurring basis are as follows: SCHEDULE OF FAIR VALUE RECURRING BASIS
|  | Fair value measurements at reporting date using: |
|  | Quoted prices in active markets for identical liabilities (Level 1) |  |  | Significant other observable inputs (Level 2) |  |  | Significant unobservable inputs (Level 3) |  |  | Total Fair Value |
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Marketable securities as of December 31, 2024 |  | $ | 10,184,701 |  |  | $ | - |  |  | $ | - |  |  | $ | 10,184,701 |
Marketable securities as of December 31, 2023 |  | $ | 10,181,618 |  |  | $ | - |  |  | $ | - |  |  | $ | 10,181,618 |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant liabilities as of December 31, 2024 |  | $ | - |  |  | $ | - |  |  | $ | 2,520,851 |  |  | $ | 2,520,851 |
Warrant liabilities as of December 31, 2023 |  | $ | - |  |  | $ | - |  |  | $ | 1,543,953 |  |  | $ | 1,543,953 |

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/825/tableOfContent + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration